相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacological inactivation of CDK2 inhibits MYC/BCL-XL-driven leukemia in vivo through induction of cellular senescence
Wesam Bazzar et al.
CELL CYCLE (2021)
Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
Stephen S. Y. Lam et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Synthesis of Biologically Active Molecules through Multicomponent Reactions
Daniel Insuasty et al.
MOLECULES (2020)
The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with anFLT3Mutation
Kyriaki Tzogani et al.
ONCOLOGIST (2020)
Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia
Yue Zhong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade
Ting Yuan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity
Eva Reznickova et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Design and Synthesis of 4-(Heterocyclic Substituted Amino)-1H-Pyrazole-3-Carboxamide Derivatives and Their Potent Activity against Acute Myeloid Leukemia (AML)
Yanle Zhi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines
Neetu Dayal et al.
FUTURE MEDICINAL CHEMISTRY (2018)
Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3-and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia
Yue Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations
Tomas Gucky et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Imidazo[1,2-c]pyrimidin-5(6H)-one as a novel core of cyclin-dependent kinase 2 inhibitors: Synthesis, activity measurement, docking, and quantum mechanical scoring
Haresh Ajani et al.
JOURNAL OF MOLECULAR RECOGNITION (2018)
How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?
Radek Jorda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia
Michael R. Grunwald et al.
SEMINARS IN HEMATOLOGY (2015)
Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
Julie A. Zorn et al.
PLOS ONE (2015)
Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3
Zhihong Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer
Anthony D. William et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Survey of Activated FLT3 Signaling in Leukemia
Ting-lei Gu et al.
PLOS ONE (2011)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
分享论文
